New hope for stubborn GIST: experimental drug DCC-2618 enters safety testing
NCT ID NCT07618377
First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times
Summary
This early-stage study tests the safety of an experimental drug called DCC-2618 in 10 people with advanced gastrointestinal stromal tumor (GIST) that has not responded to or cannot tolerate at least three prior treatments. The main goal is to see what side effects occur. This is not a cure, but aims to control the disease in patients with few remaining options.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Center Hospital
RECRUITINGTokyo, Chuo-ku, Japan
-
National Cancer Center Hospital East
RECRUITINGKashiwa, Chiba, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Brain-Cancer drug take on a stubborn stomach tumor?
- Study aims to pinpoint ideal imatinib dose for GIST patients
- New study aims to close gaps in cancer care for black patients
- 15,000 cancer Patients' data to unlock surgery secrets
- New hope for Drug-Resistant stomach cancer? sorafenib trial underway
- New drug cocktail targets tough stomach cancer in Last-Resort patients